Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 7;20(29):9759-74.
doi: 10.3748/wjg.v20.i29.9759.

Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer

Małgorzata Muc-Wierzgoń  1 , Ewa Nowakowska-Zajdel  1 , Sylwia Dzięgielewska-Gęsiak  1 , Teresa Kokot  1 , Katarzyna Klakla  1 , Edyta Fatyga  1 , Elżbieta Grochowska-Niedworok  1 , Dariusz Waniczek  1 , Janusz Wierzgoń  1
Affiliations
Review

Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer

Małgorzata Muc-Wierzgoń et al. World J Gastroenterol. .

Abstract

Advances in genomics, molecular pathology and metabolism have generated many candidate biomarkers of colorectal cancer with potential clinical value. Epidemiological and biological studies suggest a role for adiposity, dyslipidaemia, hyperinsulinemia, altered glucose homeostasis, and elevated expression of insulin-like growth factor (IGF) axis members in the risk and prognosis of cancer. This review discusses some recent past and current approaches being taken by researches in obesity and metabolic disorders. The authors describe three main systems as the most studied metabolic candidates of carcinogenesis: dyslipidemias, adipokines and insulin/IGF axis. However, each of these components is unsuccessful in defining the diseases risk and progression, while their co-occurrence increases cancer incidence and mortality in both men and women.

Keywords: Adipokines; Colorectal cancer; Dyslipidemias; Insulin-like growth factor-system; Metabolic biomarkers; Prognosis; Risk.

PubMed Disclaimer

References

    1. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113:2335–2362. - PubMed
    1. Montgomery JE, Brown JR. Metabolic biomarkers for predicting cardiovascular disease. Vasc Health Risk Manag. 2013;9:37–45. - PMC - PubMed
    1. Hojs R, Bevc S, Ekart R. Biomarkers in hemodialysis patients. Adv Clin Chem. 2012;57:29–56. - PubMed
    1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. - PubMed
    1. Brünner N. What Is the Difference Between “Predictive and Prognostic Biomarkers”? Can you Give Some Examples? Connection. 2009:13: 18–19.